New York, New York (PRWEB) May 03, 2014
A Nevada Circuit Court Judge overseeing an Actos lawsuit (http://www.theactoslawsuitcenter.com/ ) trial in Las Vegas has agreed to impose sanctions on attorneys for Takeda Pharmaceuticals, after finding that they repeatedly engaged in “disrespectful” conduct over the course of the proceeding. In an Order dated April 30th, District Judge Kerry Earley wrote that the lawyers had violated her pretrial evidentiary rulings nine times during the Actos trial. To penalize the legal team, she ruled that jurors will be told of the attorneys’ conduct in a jury instruction she will read just prior to closing arguments. The Order also indicated that the judge will impose monetary sanctions for any future violation of her orders, and that she was reserving her right to remove any attorney should future misconduct “rise to the level of intentional, extreme, vexatious or egregious behavior.” (Case Nos. A-13-680556, A-13-680922)
“Our Firm is monitoring developments in this trial very closely, as we are representing a number of Actos lawsuit clients who have put forth allegations similar to those at issue in this case,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.
Actos Bladder Cancer Allegations
According to court documents, the Nevada trial involves two individual Actos lawsuits filed by Las Vegas women who allegedly developed bladder cancer after using the medication for more than one year. The women are seeking a multi-billion verdict, which according to court filings, would be the largest ever awarded in the state. Jury deliberations in the case are expected to begin later this month.
Court records indicate that lawsuits involving Actos and bladder cancer began to mount shortly after the U.S. Food & Drug Administration (FDA) warned in June 2011 that extended use of the drug could increase the risk that a patient will develop bladder cancer. Some 3,000 such claims are now pending in courts around the country, though most have been filed in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. All of the Actos lawsuits allege that Takeda and other defendants concealed the risk of bladder cancer associated with long-term use of the drug. (In re: Actos Product Liability Litigation, MDL No. 2299)
On April 7, 2014, the first federal trial of an Actos bladder cancer claim concluded in the Western District of Louisiana when the jury returned a multi-billion verdict favoring the plaintiff. In addition to a $1.475 million compensatory damage award, court documents show that Takeda and Eli Lilly & Co. were ordered to pay the plaintiff a combined $9 billion in punitive damages. (Allen v. Takeda Pharmaceuticals North America Inc., 12-cv-00064)
Individuals who allegedly developed bladder cancer due to their use of Actos may be eligible to file an Actos lawsuit. To learn more about the nationwide Actos bladder cancer litigation, please visit Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP